Prevention of first variceal bleed: An appraisal of current therapies

American Journal of Gastroenterology

Volumn 93, Issue 12, 1998, Pages 2348-2358

  Shahi, Hansa M ^a   Sarin, Shiv K ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NADOLOL; NITRATE; PROPRANOLOL; SEROTONIN ANTAGONIST; SPIRONOLACTONE; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC SURGERY; ESOPHAGUS VARICES BLEEDING; HUMAN; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ENDOSCOPY; ENDOSCOPY, GASTROINTESTINAL; HEMORRHAGE; HUMANS; LIGATION; SCLEROTHERAPY; VARICOSE VEINS;

EID: 0032417143     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00589.x     Document Type: Review

References (95)

1. 1. Burroughs AK, D' Heygere F, McIntyre N. Pitfalls in studies of prophylactic therapy for variceal bleeding in cirrhotics. Hepatology 1986;6:1407-13.
2. 2. Lebrec D. Pharmacological prevention of variceal bleeding and rebleeding. J Hepatol 1993;17(suppl 2):S29-33.
3. 3. North Italian Endoscopic Club for the study and treatment of esophageal varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1988;319:983-9.
4. 4. Burroughs AK. The natural history of varices. J Hepatol 1993;17(suppl 2):S10-3.
5. 5. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-9.
6. 6. Jackson FC, Perrin EB, Smith AG, et al. A clinical investigation of the portacaval shunt: Survival analysis of the prophylactic operation. Am J Surg 1968;11:22-42.
7. 7. Resnick RH, Chalmers TC, Ishihara AM, et al. A controlled study of the prophylactic portacaval shunt: A final report. Ann Intern Med 1969;70:675-88.
8. 8. Conn HO, Lindenmuth WW, May CJ, et al. Prophylactic portacaval anastomosis: A tale of two studies. Medicine 1972;51:27-40.
9. 9. Pascal JP, Cales P, and a Multicenter Study Group. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-61.
10. 10. Ideo G, Bellati G, Fesce E, et al. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: A prospective, randomized study. Hepatology 1988;8:6-9.
11. 11. Lebrec D, Poynard T, Capron JP, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J Hepatol 1988;7:118-25.
12. 12. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. J Hepatol 1989;9:75-83.
13. 13. Andreani T, Poupon RE, Balkau B, et al. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: Results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology 1990;12:1413-9.
14. 14. Conn HO, Grace N, Bosch J, et al. Propranolol in the prevention of the first hemorrhage from esophageal varices; results of a randomized double blind cooperative clinical trial. Hepatology 1991;13:902-12.
15. 15. The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients. A randomized multicenter trial. Hepatology 1991;14:1016-24.
16. 16. Strauss E, deSa MF, Albano A, et al. A randomized controlled trial for the prevention of the first upper gastrointestinal bleeding due to portal hypertension in cirrhosis: Sclerotherapy or propranolol versus control groups. Hepatology 1988;8:1395 (abstract).
17. 17. Colman J, Jones P, Finch C, et al. Propranolol in the prevention of variceal hemorrhage in alcoholic cirrhotic patients. Hepatology 1990; 12:851 (abstract).
18. 18. Price HL, Cooperman LH, Warden JC. Control of the splanchnic circulation in man: Role of beta-adrenergic receptors. Circ Res 1967; 21:333.
19. 19. Bosch J, Mastai R, Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984;4:1200-5.
20. 20. Gaiani S, Bolondi L, Fenyves D, et al. Effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Hepatology 1991;14:824-9.
21. 21. Hayes PC, Davis JM, Lewis JA, et al. Meta-analysis of value of propranolol in prevention of variceal hemorrhage. Lancet 1990;336: 153-6.
22. 22. Poynard T, Cales P, Pasta L, et al., and the Franco-Italian Multicenter Study Group. Beta-adrenergic antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med 1991;324:1532-8.
23. 23. Pagliaro L, D'Amico G, Sorensen TIA, et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992;117:59-70.
24. 24. Pagliaro L, Burroughs AK, Sorensen TIA, et al. Betablockers for preventing variceal bleeding. Lancet 1990;336:1001-2.
25. 25. Teran JC, Imperiale TF, Mullen KD, et al. Primary prophylaxis of variceal bleeding in cirrhosis: A cost-effectiveness analysis. Gastroenterology 1997;112:473-82.
26. 26. Conn HO. Prophylactic propranolol: The first big step. Hepatology 1988;8:167-70.
27. 27. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99: 1401-7.
28. 28. Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Portal pressure, presence of gastro-esophageal varices and bleeding. Hepatology 1985; 5:419-24.
29. 29. Grace ND. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Ame 1992;21:149-61.
30. 30. Cales P, Desmorat H, Vinel JP, et al. Incidence of large esophageal varices in patients with cirrhosis: Application to prophylaxis of first bleeding. Gut 1990;31:1298-1302.
31. 31. Grace ND, Conn HO, Groszmann RJ, et al. Propranolol for prevention of first esophageal variceal hemorrhage (EVH): A lifetime commitment? Hepatology 1990;12:407 (abstract).
32. 32. Angelico M, Carli L, Piat C, et al. Isosorbide-5 mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 1993;104:1460-5.
33. 33. Merkel C, Gatta A, Amodio P, et al. Nadolol or nadolol plus isosorbide 5-mononitrate in the prophylaxis of first variceal bleeding in patients with cirrhosis. Interim analysis of a multicenter study. J Hepatol 1993;8(suppl 1) S147-8.
34. 34. Merkel C, Martin R, Enzo E, et al. Randomised controlled trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996;348:1677-81.
35. 35. Okumura H, Aramaki T, Katsuta Y, et al. Reduction in HVPG as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.
36. 36. Garcia-Pagan JC, Salmeron JM, Feu F, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994;19:1095-9.
37. 37. Nevens F, Lijnen P, Vanbilloen H, et al. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996;23:1047-52.
38. 38. Van de Casteele M, Van Roey G, Nevens F, et al. Effects of varying doses of spironolactone with and without nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Hepatology 1996;24:1492-6.
39. 39. Bosch J, Garcia-Pagan JC, Feu F, et al. New approaches in the pharmacologic treatment of portal hypertension. J Hepatol 1993; 17(suppl 2):S41-5.
40. 40. Kravetz D, Romero G, Bildozola M, et al. Nadolol plus spironolactone is not more effective than nadolol alone in decreasing portal pressure in cirrhotic patients. Hepatology 1996;24:206A (abstract).
41. 41. Mastai R, Giroux L, Semret M, et al. Ritanserin decreases portal pressure in conscious and unrestrained cirrhotic rats. Gastroenterology 1990;98:141-5.
42. 42. Nevens F, Pizcueta MP, Fernandez M, et al. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats. Hepatology 1991;14:1174-8.
43. 43. Kaumann AJ, Morgan JS, Groszmann RJ. ICI,169,369 selectively blocks 5-hydroxytryptamin 2 receptors and lowers portal pressure in portal hypertensive rats. Gastroenterology 1988;95:1601-6.
44. 44. Hadengue A, Lee SS, Moreau R, et al. Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanisms in portal hypertension. Hepatology 1987;7:644-7.
45. 45. Vorobioff J, Garcia-Tsao G, Groszmann RJ, et al. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 1989;9:88-91.
46. 46. Navasa M, Bosch J, Reichen J, et al. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology 1988;8:850-4.
47. 47. Conn HO, Lindenmuth WW, May CJ, et al. Prophylactic portacaval anastomosis in cirrhotic patients with esophageal varices. N Engl J Med 1965;272:1255-63.
48. 48. Grace ND, Conn HO, Resnick RH, et al. Distal splenorenal vs portal-systemic shunts after hemorrhage from varices: A randomized controlled trial. Hepatology 1988;8:1475-81.
49. 49. Inokuchi K. Co-operative Study Group of Portal Hypertension of Japan. Improved survival following prophylactic portal non-decompression surgery for esophageal varices. Hepatology 1990;12:1-6.
50. 50. Conn HO. Why is prophylactic portal non-decompressive surgery effective in preventing hemorrhage from esophageal varices? Hepatology 1990;12:166-8.
51. 51. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: A meta-analytic review. Hepatology 1995;22:332-54.
52. 52. Paquet KJ. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices: A prospective controlled randomized trial. Endoscopy 1982;14:4-5.
53. 53. Witzel L, Wolbergs E, Merki H. Prophylactic endoscopic sclerotherapy of esophageal varices. Lancet 1985;1:773-5.
54. 54. Koch H, Henning H, Grimm H, et al. Prophylactic sclerosing of esophageal varices: Results of a prospective controlled study. Endoscopy 1986;18:40-3.
55. 55. Kobe VE, Zipprich B, Schentke KU, et al. Prophylactic endoscopic sclerotherapy of esophageal varices: A prospective randomized trial. Endoscopy 1990;22:245-8.
56. 56. Santangelo WC, Dueno MI, Estes BL, et al. Prophylactic sclerotherapy of large esophageal varices. N Engl J Med 1988;318:814-8.
57. 57. Sauerbruch T, Wotzka R, Kopcke W, et al. Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis. N Engl J Med 1988;319:8-15.
58. 58. Piai G, Cipolletta A, Claar M, et al. Prophylactic sclerotherapy of high-risk esophageal varices: Results of a multicentric prospective controlled trial. Hepatology 1988;8:1495-500.
59. 59. Potzi R, Bauer P, Reichel W, et al. Prophylactic endoscopic sclerotherapy of esophageal varices in liver cirrhosis. A multicenter, prospective, controlled randomized trial in Vienna. Gut 1989;30: 873-9.
60. 60. Russo A, Giannone G, Magnano A, et al. Prophylactic sclerotherapy in non-alcoholic liver cirrhosis: preliminary results of a prospective, controlled randomized trial. World J Surg 1989;13:149-53.
61. 61. Triger DR, Smart HL, Hosking SW, et al. Prophylactic sclerotherapy for esophageal varices: longterm results of a single-center trial. Hepatology 1991;13:117-23.
62. 62. The Veterans Affairs Co-operative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. N Engl J Med 1991;324:1779-84.
63. 63. De Franchis R, Primignani M, Arcidiacono PG, et al. Prophylactic sclerotherapy in high-risk cirrhotics selected by endoscopic criteria. Gastroenterology 1991;101:1087-93.
64. 64. Fleig WE, Stange EF, Wordehoff D, et al. Prophylactic versus therapeutic sclerotherapy in cirrhotic patients with large esophageal varices and no previous hemorrhage: A randomized clinical trial. Hepatology 1988;8:1242 (abstract).
65. 65. Saggioro A, Pallini P, Chiozzini G, et al. Prophylactic sclerotherapy: A controlled study. Dig Dis Sci 1986;31(suppl 10):504S (abstract).
66. 66. Wordehoff D, Spech RJ. Prophylaktische oesophagusvarizen sklerosierung. Deutsche Medizinische Wochenschrift 1987;112:947-51.
67. 67. Planas R, Boix J, Dominguez M, et al. Prophylactic sclerosis of esophageal varices (EV). Prospective trial. J Hepatol 1989;9(suppl 1):S73 (abstract).
68. 68. Pagliaro L, Burroughs AK, Sorensen TIA, et al. Therapeutic controversies and randomized controlled trials (RCTs): Prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int 1989;2:71-84.
69. 69. Fardy JM, Laupacis A. A meta-analysis of prophylactic endoscopic sclerotherapy for esophageal varices. Am J Gastroenterol 1994;89: 1938-48.
70. 70. Snady H, Feinman L, Lieber CS. Evaluation of propranolol and sclerotherapy, alone and in combination, for the prophylactic treatment of esophageal varices. Am J Gastroenterol 1988;83:1065 (abstract).
71. 71. Van Ruiswyk J, Byrd JC. Efficacy of prophylactic sclerotherapy for prevention of a first variceal hemorrhage. Gastroenterology 1992;102: 587-97.
72. 72. Paquet KJ, Kalk JF, Kline CP, et al. Prophylactic sclerotherapy for esophageal varices in high-risk cirrhotic patients selected by endoscopic and hemodynamic criteria: A randomized single-center controlled trial. Endoscopy 1994;26:734-40.
73. 73. Van Stiegmann G, Goff JS, Sun JH, et al. Endoscopic ligation of esophageal varices. Am J Surg 1990;159:21-6.
74. 74. Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992;326:1527-32.
75. 75. Laine L, El-Newihi HM, Migikovsky B, et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 1993;119:1-7.
76. 76. Gimson AES, Ramage JK, Panoz MZ, et al. Randomized trial of variceal banding ligation versus injection sclerotherapy for bleeding esophageal varices. Lancet 1993;342:391-4.
77. 77. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal varices and bleeding: A metaanalysis. Ann Intern Med 1995;123:280-7.
78. 78. Sarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: Influence on gastropathy, gastric varices, and variceal recurrence. J Hepatol 1997;26:826-32.
79. 79. Sarin SK, Guptan RC, Jain AK, et al. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding. Euro J Gastroenterol Hepatol 1996;8:337-42.
80. 80. Sarin SR, Nanda R, Vij JC, et al. Esophageal ulceration after sclerotherapy - a complication or an accompaniment? Endoscopy 1986;18: 44-5.
81. 81. Sarin SK, Sachdev G, Nanda R, et al. Endoscopic sclerotherapy using absolute alcohol. Gut 1985;20:120-4.
82. 82. Przemioslo R, Mc Nair ANB, Williams R. Oesophageal varices: Prophylactic treatment by endoscopic banding ligation prior to index bleed. Eur J Gastroenterol Hepatol 1996;8:329-31.
83. 83. Lay C-S, Tsai Y-T, Teg C-Y, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 1997;25:1346-50.
84. 84. Sarin SK, Lamba GS, Kumar M, et al. Randomized trial of propranolol versus endoscopic variceal ligation (EVL) in the primary prophylaxis of bleeding from high-risk varices in cirrhosis: An interim analysis Hepatology 1997;26:928A (abstract).
85. 85. Gameel K, Waked I, Saleh S, et al. Prophylactic endoscopic variceal band ligation (EVL) versus sclerotherapy (ES) for the prevention of variceal bleeding: An interim report of a prospective randomized controlled trial in schistosomal portal hypertension. Hepatology 1995; 22:251A (abstract).
86. 86. Sarin SK, Groszmann RJ, Mosca PG, et al. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest 1991;87: 1032-6.
87. 87. Lin HC, Soubrane O, Cailmail S, et al. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol 1991;13:213-9.
88. 88. Lin HC, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein stenosed rats. Hepatology 1991; 14:325-30.
89. 89. Cales P. Groupe Francais de La Prevention Pre-primaire. Propranolol does not decrease the development of large esophageal varices in patients with cirrhosis. A controlled study. Hepatology 1995;22:155A (abstract).
90. 90. Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997;72:1137-40.
91. 91. Christensen E, Faverholdt L, Schlichting P, et al. Aspects of natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisolone. Gastroenterology 1981;81:944-52.
92. 92. D'Amico G, Pasta L, Vizzine GB, et al. Natural history of cirrhosis. J Hepatol 1990;13:S22 (abstract).
93. 93. Beppu K, Inokuchi K, Koyanagy N, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981;27: 213-8.
94. 94. Sarin SK, Sundaram KR, Ahuja RK. Predictors of variceal bleeding: An analysis of clinical, endoscopic, and hemodynamic variables, with special reference to intravariceal pressure. Gut 1989;30:1757-64.
95. 95. McCormick PA, Patch D, Greenslade L, et al. Clinical versus hemodynamic response to drugs in portal hypertension. Hepatology 1995; 22:255A (abstract).